{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T11:12:32Z","timestamp":1767611552595,"version":"3.40.4"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,6,22]],"date-time":"2021-06-22T00:00:00Z","timestamp":1624320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,6,22]],"date-time":"2021-06-22T00:00:00Z","timestamp":1624320000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1007\/s10549-021-06186-8","type":"journal-article","created":{"date-parts":[[2021,6,22]],"date-time":"2021-06-22T19:02:27Z","timestamp":1624388547000},"page":"343-350","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Developing patient-centred strategies to optimize the management of vasomotor symptoms in breast cancer patients: a survey of health care providers"],"prefix":"10.1007","volume":"188","author":[{"given":"Katherine Marie","family":"Cole","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Clemons","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meshari","family":"Alzahrani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gail","family":"Larocque","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fiona","family":"MacDonald","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Vandermeer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"Hutton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ardelle","family":"Piper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Greg","family":"Pond","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0323-6372","authenticated-orcid":false,"given":"Sharon","family":"McGee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,6,22]]},"reference":[{"issue":"9453","key":"6186_CR1","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/S0140-6736(04)17666-6","volume":"365","author":"A Howell","year":"2005","unstructured":"Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, Hoctin-Boes G, Houghton J, Locker GY, Tobias JS, Group AT (2005) Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years\u2019 adjuvant treatment for breast cancer. Lancet 365(9453):60\u201362. https:\/\/doi.org\/10.1016\/S0140-6736(04)17666-6","journal-title":"Lancet"},{"issue":"2","key":"6186_CR2","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1056\/NEJMoa1404037","volume":"371","author":"O Pagani","year":"2014","unstructured":"Pagani O, Regan MM, Walley BA, Fleming GF, Colleoni M, Lang I, Gomez HL, Tondini C, Burstein HJ, Perez EA, Ciruelos E, Stearns V, Bonnefoi HR, Martino S, Geyer CE Jr, Pinotti G, Puglisi F, Crivellari D, Ruhstaller T, Winer EP, Rabaglio-Poretti M, Maibach R, Ruepp B, Giobbie-Hurder A, Price KN, Bernhard J, Luo W, Ribi K, Viale G, Coates AS, Gelber RD, Goldhirsch A, Francis PA, Text, Investigators S, International Breast Cancer Study G (2014) Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med 371(2):107\u2013118. https:\/\/doi.org\/10.1056\/NEJMoa1404037","journal-title":"N Engl J Med"},{"issue":"4","key":"6186_CR3","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1080\/0167482X.2017.1350163","volume":"38","author":"D Fenlon","year":"2017","unstructured":"Fenlon D, Morgan A, Khambaita P, Mistry P, Dunn J, Ah-See ML, Pennery E, Hunter MS, Party NCBCSW (2017) Management of hot flushes in UK breast cancer patients: clinician and patient perspectives. J Psychosom Obstet Gynaecol 38(4):276\u2013283. https:\/\/doi.org\/10.1080\/0167482X.2017.1350163","journal-title":"J Psychosom Obstet Gynaecol"},{"issue":"6","key":"6186_CR4","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/s0885-3924(00)00142-1","volume":"19","author":"KD Stein","year":"2000","unstructured":"Stein KD, Jacobsen PB, Hann DM, Greenberg H, Lyman G (2000) Impact of hot flashes on quality of life among postmenopausal women being treated for breast cancer. J Pain Symptom Manage 19(6):436\u2013445. https:\/\/doi.org\/10.1016\/s0885-3924(00)00142-1","journal-title":"J Pain Symptom Manage"},{"issue":"21","key":"6186_CR5","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.1200\/JCO.2015.63.8619","volume":"34","author":"JH Chirgwin","year":"2016","unstructured":"Chirgwin JH, Giobbie-Hurder A, Coates AS, Price KN, Ejlertsen B, Debled M, Gelber RD, Goldhirsch A, Smith I, Rabaglio M, Forbes JF, Neven P, L\u00e1ng I, Colleoni M, Th\u00fcrlimann B (2016) Treatment Adherence and Its Impact on Disease-Free Survival in the Breast International Group 1\u201398 Trial of Tamoxifen and Letrozole, Alone and in Sequence. J Clin Oncol 34(21):2452\u20132459. https:\/\/doi.org\/10.1200\/JCO.2015.63.8619","journal-title":"J Clin Oncol"},{"issue":"1","key":"6186_CR6","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1097\/01.AOG.0000441353.20693.78","volume":"123","author":"ACOG","year":"2014","unstructured":"ACOG (2014) Practice Bulletin No. 141: management of menopausal symptoms. Obstet Gynecol 123(1):202\u2013216. https:\/\/doi.org\/10.1097\/01.AOG.0000441353.20693.78","journal-title":"Obstet Gynecol"},{"issue":"4","key":"6186_CR7","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1056\/NEJM200101253440407","volume":"344","author":"M Clemons","year":"2001","unstructured":"Clemons M, Goss P (2001) Estrogen and the risk of breast cancer. N Engl J Med 344(4):276\u2013285. https:\/\/doi.org\/10.1056\/NEJM200101253440407","journal-title":"N Engl J Med"},{"issue":"4","key":"6186_CR8","doi-asserted-by":"publisher","first-page":"E86","DOI":"10.1188\/20.ONF.E86-E106","volume":"47","author":"B Hutton","year":"2020","unstructured":"Hutton B, Hersi M, Cheng W, Pratt M, Barbeau P, Mazzarello S, Ahmadzai N, Skidmore B, Morgan SC, Bordeleau L, Ginex PK, Sadeghirad B, Morgan RL, Cole KM, Clemons M (2020) Comparing Interventions for Management of Hot Flashes in Patients With Breast and Prostate Cancer: A Systematic Review With Meta-Analyses. Oncol Nurs Forum 47(4):E86\u2013E106. https:\/\/doi.org\/10.1188\/20.ONF.E86-E106","journal-title":"Oncol Nurs Forum"},{"issue":"1","key":"6186_CR9","doi-asserted-by":"publisher","first-page":"e40","DOI":"10.1016\/j.clbc.2018.08.012","volume":"19","author":"SF McGee","year":"2019","unstructured":"McGee SF, Vandermeer L, Mazzarello S, Sienkiewicz M, Stober C, Hutton B, Fergusson D, Hilton J, Caudrelier JM, Blanchette P, Clemons M (2019) Physician Survey of Timing of Adjuvant Endocrine Therapy Relative to Radiotherapy in Early Stage Breast Cancer Patients. Clin Breast Cancer 19(1):e40\u2013e47. https:\/\/doi.org\/10.1016\/j.clbc.2018.08.012","journal-title":"Clin Breast Cancer"},{"issue":"29","key":"6186_CR10","doi-asserted-by":"publisher","first-page":"3862","DOI":"10.1200\/JCO.2010.33.1298","volume":"29","author":"AH Boekhout","year":"2011","unstructured":"Boekhout AH, Vincent AD, Dalesio OB, van den Bosch J, Foekema-T\u00f6ns JH, Adriaansz S, Sprangers S, Nuijen B, Beijnen JH, Schellens JH (2011) Management of hot flashes in patients who have breast cancer with venlafaxine and clonidine: a randomized, double-blind, placebo-controlled trial. J Clin Oncol 29(29):3862\u20133868. https:\/\/doi.org\/10.1200\/JCO.2010.33.1298","journal-title":"J Clin Oncol"},{"issue":"1","key":"6186_CR11","doi-asserted-by":"publisher","first-page":"43","DOI":"10.3322\/caac.21319","volume":"66","author":"CD Runowicz","year":"2016","unstructured":"Runowicz CD, Leach CR, Henry NL, Henry KS, Mackey HT, Cowens-Alvarado RL, Cannady RS, Pratt-Chapman ML, Edge SB, Jacobs LA, Hurria A, Marks LB, LaMonte SJ, Warner E, Lyman GH, Ganz PA (2016) American Cancer Society\/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline. CA Cancer J Clin 66(1):43\u201373. https:\/\/doi.org\/10.3322\/caac.21319","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"6186_CR12","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1200\/JCO.2009.23.5150","volume":"28","author":"EM Walker","year":"2010","unstructured":"Walker EM, Rodriguez AI, Kohn B, Ball RM, Pegg J, Pocock JR, Nunez R, Peterson E, Jakary S, Levine RA (2010) Acupuncture versus venlafaxine for the management of vasomotor symptoms in patients with hormone receptor-positive breast cancer: a randomized controlled trial. J Clin Oncol 28(4):634\u2013640. https:\/\/doi.org\/10.1200\/JCO.2009.23.5150","journal-title":"J Clin Oncol"},{"issue":"4","key":"6186_CR13","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1093\/annonc\/mdl478","volume":"18","author":"S Loibl","year":"2007","unstructured":"Loibl S, Schwedler K, von Minckwitz G, Strohmeier R, Mehta KM, Kaufmann M (2007) Venlafaxine is superior to clonidine as treatment of hot flashes in breast cancer patients\u2013a double-blind, randomized study. Ann Oncol 18(4):689\u2013693. https:\/\/doi.org\/10.1093\/annonc\/mdl478","journal-title":"Ann Oncol"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-021-06186-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-021-06186-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-021-06186-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T09:17:01Z","timestamp":1744190221000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-021-06186-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,22]]},"references-count":13,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["6186"],"URL":"https:\/\/doi.org\/10.1007\/s10549-021-06186-8","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"type":"print","value":"0167-6806"},{"type":"electronic","value":"1573-7217"}],"subject":[],"published":{"date-parts":[[2021,6,22]]},"assertion":[{"value":"3 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"SMG reports receipt of honorarium from Novartis for insights on management of breast cancer patients. BH and MC reports consulting fees from Cornerstone Research, outside the submitted works. All other authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the Ontario Cancer Research Ethics Board (OCREB).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Participation and completion of the survey implied consent to participate.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Participation and completion of the survey implied consent to publication of aggregate survey findings.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}